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During pulmonary inflammation increased amounts of reactive oxygen species (ROS) and reactive nitrogen 
intermediates (RNI) are produced as a consequence of phagocyte respiratory burst. One of the manifestations of 
these free radical-mediated processes is lipid peroxidation (LP). 
The aim of our study was to assess the concentration of lipid peroxidation products (LPPs), conjugated diens 
(CD) and malondialdehyde (MDA), in patients with active TB. 
Forty-two patients were enrolled into the study. Half (group I) had advanced TB and were sputum smear-positive. 
The remainder (group II) had only small radiographical changes and were sputum smear-negative. Serum 
concentrations of CD and MDA were measured at days 0,7,14 and 28 in group I and day 0 in group II. We found 
that in all patients with active TB Co, (1.0 f O.O5A,,,) and ChlDA (2.01 f 0.16 nmol dl - ‘) were significantly 
elevated compared to healthy controls (0.67 & O.O3A,,, and 1.36 f 0.08 nmol dl- ‘, respectively) (PcO.001). The 
highest levels of LPPs were in patients with advanced TB. These concentrations were stable during the first month 
of anti-tuberculous therapy. 
Our data indicated that, as in bacterial pneumonia, LPPs were enhanced in active TB. The levels of LPPs 
depended on the form of the disease as they were higher in subjects with advanced disease than in those with only 
small radiographical changes. Further studies are needed to assess the role of antioxidants as adjuvant therapy in 
patients with pulmonary TB. 
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Introduction 
About one-third of world’s population is thought to be 
infected with Mycobacterium tuberculosis (1). Mycobacteria 
are intracellular pathogens which grow and replicate in the 
host macrophages. After phagocytosis survival of myco- 
bacteria depends on their ability to avoid destruction 
by macrophages. It is well known that phagocytes, e.g. 
neutrophils, macrophages and monocytes, undergo respir- 
atory burst after contact with microorganism. These cells 
possess the capacity to generate huge amounts of reactive 
oxygen species (ROS) and reactive nitrogen intermediates 
(RNI), which are essential for the destruction of ingested 
microorganisms but also contribute to inflammatory injury 
of host tissue. 
Increased amounts of ROS and RN1 are produced as a 
consequence of phagocyte respiratory burst and serve as 
markers of the free-radical-mediated processes. These 
reactive oxygen and nitrogen species induce lipid peroxi- 
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dation (LP), a chain process which affects unsaturated fatty 
acids mainly localized in cell membranes, in which such 
products as conjugated diens (CD) and malondialdehyde 
(MDA) are generated (2). Lipid peroxidation products 
(LPPs) diffuse from the site of inflammation and can be 
measured in the blood. 
It was well established in an animal model as well as in 
patients that serum concentrations of LPPs were increased 
in pulmonary inflammation (3-5). In a previous study we 
have demonstrated that in subjects with pneumonia concen- 
trations of lipid peroxides and malondialdehyde were sig- 
nificantly enhanced and they correlated with other markers 
of inflammation like erythrocyte sedimentation rate (ESR) 
and white blood cell count (WBC) (3). In mycobacterial 
infection the interactions between macrophages and lym- 
phocytes mediated by the cytokines seem to be the most 
important in host defence (6,7). Chan et al. (8) have shown 
in a murine model that inhibition of Mycobacterium 
tuberculosis growth is independent of the generation of 
ROS. On the other hand, MacMicking et aZ. (9) have 
recently demonstrated that among mice with genetic 
inability to produce inducible nitric oxide synthase (iNOS) 
replication of Mycobacterium tuberculosis is faster than in 
wild-type animals. Taking these data into consideration it 
can not be excluded that enhanced generation of ROS may 
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occur in subjects with active TB, but this process may have 
a limited, if any, role in the defence against Mycobacterium 
tuberculosis. Therefore in our study we decided to investi- 
gate whether: (1) LP would enhance during active pulmon- 
ary TB; (2) LP would depend on the form of TB: advanced 
versus small radiographical changes; and (3) if 1 month of 




Forty-two patients with pulmonary tuberculosis treated in 
Department of Pneumology and Allergology in Lodi were 
enrolled into the study. Group I consisted of 21 patients (14 
men and seven women; mean age 50 l 2 years; 15 smokers). 
All of them had: (1) clinical manifestations of TB (tempera- 
ture, cough, sweat, weight loss, fatigue); (2) advanced 
radiographical changes (at least three zones on X-ray); (3) 
positive sputum smear. Group II consisted of 21 patients 
(eight men and 13 women, mean age 43.3 f 3 years; 12 
smokers) with: (1) small radiographic changes (one zone on 
X-ray); (2) usually no symptoms; (3) negative sputum 
smear. All patients from the group II revealed radiographi- 
cal regression during anti-tuberculous treatment, but only 
nine of them had bacteriological confirmation either by 
culture on Lowenstein-Jensen medium, radiometric system 
of Bactec 460 or Ligase Chain Reaction (LCx-Abbott) 
diagnostic methods. The patients had been treated with 
standard chemotherapy: isoniazid (INH 5 mg kg - ‘day - ‘), 
pyrazinamide (PZA 25 mg kg - ‘day - I), rifampin (RFP 
lomgkgg’day-‘, no more than 0.6 g day - ‘) daily for 2 
months and then INH (15 mg kg - ‘) plus RFP (0.6 g) twice 
a week for the next 4 months. Patients from the group I also 
received streptomycin (SM 15 mg kg- ‘day- ‘, no more 
than 1 g day - ‘) for the first 2 months of treatment. During 
the study patients did not receive any known antioxidants 
such as N-acetylcysteine, ambroxol, vitamin C or E (lo- 
13). In group I, on days 0 (pre-treatment), 7, 14 and 28 
blood samples were taken for the assessment of CD and 
MDA. In the group II blood samples were taken only 
on day 0, because of low pre-treatment values and lack 
of changes in LPPs concentration in preliminary studies 
performed in this group. 
On days 0 and 28, ESR and WBC were also performed. 
Body temperature was measured at 06:OO h and 16:00 h 
each day and expressed as a mean value. An X-ray was 
taken before introducing anti-tuberculous drugs, after 1 
month of treatment and at the end of therapy. Each X-ray 
was analysed independently by two physicians. 
As a control we used 10 healthy volunteers (six men and 
four women; mean age 41 5 2 years; five smokers) without 
any changes on X-ray. They were not currently taking 
medication. It was shown that LPP concentrations were 
stable in healthy people over the few weeks of observation 
(3). 
All patients gave informed consent and the study was 
approved by the Local Ethics Committee. 
DETERMINATION OF CD AND MDA 
Conjugated diens were measured according to the method 
described previously (14). Briefly, 0.5 ml of serum were 
mixed with 7 ml of a chloroform (Ubichem Ltd, Eastleigh, 
U.K.)/methanol (POCh, Gliwice, Poland) mixture (1:2 v/v), 
shaken for 2 min and centrifuged (1500 g for 5 min). A 5 ml 
aliquot of the lower layer was mixed with 2 ml of distilled 
water acidified with HCl to pH 2.5. The solution was 
shaken again for 2 min and centrifuged as above. The 
chloroform layer was aspirated and dried under a flow of 
nitrogen. The residues were diluted with 2 ml of heptane 
and its absorbance was read against a heptane blank at 
233 nm using an Ultrospec III (Pharmacia LKB, Pharmacia 
Biotech Ltd, Cambridge, U.K.). Results were expressed in 
absorbance units. 
Malondialdehyde concentration was estimated according 
to the method of Yagi with some modifications (3,15). 
Briefly, 0.25 ml of serum were mixed with 2.5 ml of a 
0.069 M solution of phosphotungstic acid (pH 1.3-1.5) 
(Merck, Darmstadt, Germany). The sample was then cen- 
trifuged (4°C 3000 g) for 15 min and 0.5 ml of a 0.055 M 
solution of TBA (thiobarbituric acid, Sigma Chemical Co, 
St. Louis, U.S.A.) and 1 ml of distilled water were added to 
the residue. After rigorous shaking the sample was boiled 
for 60 min and again centrifuged at 6000 g for 10 min. 
TBA-reactive substances were extracted with 2 ml 
of N-butanol and measured spectrofluorometrically 
(excitation 515 nm, emission 555 nm) on a Perkin Elmer 
(Beaconsfield, U.K.) Luminescence Spectrometer (LS- 
50B). Tetramethoxypropane (0.1-10 nmol dl- ‘) (Sigma, 
St. Louis, MO, U.S.A.) was used as an external standard 
and the concentrations of TBA-reactive substances were 
expressed in nmol dl - ’ (16). 
Statistical analysis 
Results were expressed as mean & SEM. For non-paired 
samples the Student’s t-test and Kolmogorov-Smirnov test 
were used depending on sample distribution. Correlations 
were estimated by Pearson’s and Spearman’s tests, 
respectively. 
Results 
LPPs in the whole group of patients (with advanced and 
small radiographical changes) were much higher than in 
healthy controls. Cc, was I.0 f 0.05 A;,, as compared to 
0.67 f 0.03 A233 (P<O.OOl) and C,,, was 2.01 f 
0.16 nmol dl - ’ in TB patients and 1.36 & 0.08 nmol dl - ’ 
in the control group (P<O.OOl) (Fig. 1). 
Patients from group I had the highest levels of LPPs. 
The concentration of CD before treatment reached 
1.14 f 0.09 A2s3 and was significantly higher than in 
patients in group II (PcO.01) and the control group 
(PcO.05) (Fig. 2). The levels of CD did not change signifi- 
cantly during the first month of anti-tuberculous therapy: 
day 0, 1.14fO.O9A,,,; day 7, 1.22&0.07A233; day 14, 
1.2 f 0.07 Azx3; day 28, 1.15 % 0.07 Az33 (Fig. 3). 
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FIG. 1. Concentration of CD and MDA in all patients 
with TB and healthy controls. A, CD in healthy controls; 
B, CD in patients with TB; C, MDA in healthy controls; 
D, MDA in patients with TB. 
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FIG. 2. The serum concentration of CD in healthy con- 
trols, subjects with small radiographic changes (group-II) 
and patients with advanced TB (group I). 
*P<O.O5 vs. small radiographical changes; **P<O.Ol vs. 




FIG. 3. No &gnifi&nt changes of serum concentration of 
CD (0) and MDA (m) in patients with advanced TB 
during the first month of anti-tuberculous therapy. 
Also, the serum concentration of MDA in patients from 
group 1 (CMDA= 3.22 f 0.37 nmol dl - i) was higher than 
in group II (P<O.OOl) and the healthy controls (F<O.05) 
(Fig. 4). Similar to Co,, ClllDA did not differ significantly 
during the first 4 weeks of treatment: day 0, 3.22 f 
0.37 nmol dl - ‘; day 7, 2.90 f 0.18 nmol dl - ‘; day 14, 
3.21 & 0.30 nmol dl- ‘; day 28, 2.76 f 0.18 nmol dl - ’ 
(P>O.O5) (Fig,*3), 1 
10.00 *** 
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FIG. 4. The serum concentration of MDA in healthy con- 
trols, patients with small radiographic changes (group II) 
and patients with advanced TB (group I). 
*N.S. vs. small radiographical changes; **P<O*OOl vs. 
advanced TB; ***P<O.O5 vs. healthy controls. 
Apart from day 0 (r=0.37; Spearman’s test) there was a 
correlation between Cc, and C,,, in patients from group 
I during the first month of therapy: r=0.52 (PcO.05; 
Pearson’s test) on day 7; rz0.45 (PcO.05; Spearman’s test) 
on day 14; and r=0.52 (PcO.05; Pearson’s test) on day 28. 
The positive correlation between Cc, and body tempera- 
ture (rz0.43; PcO.05; Spearman’s test) was only found in 
patients with advanced TB before treatment. After 4 weeks 
of anti-tuberculous therapy all patients from group I were 
still smear-positive and only seven of them (33.3%) revealed 
small radiographical regression. There was no correlation 
between LPPs and body temperature, WBC or ESR after 
1 month of treatment. 
Mean ESR, WBC and temperature in patients from 
groups I and II are shown in Table 1. 
Patients in group II exhibited lower concentrations of 
LPPs. The level of CD was 0.85 & 0.05 A,,, and was 
significantly higher than in healthy controls C,,=O.67 & 
0.03 A,,, (P<O.O5), but C,,, was 1.40 f 0.16 nmol dl- ’ 
and did not differ from the control group CMMDA= 
1.36 & 0.08 nmol dl- i (P>O.O5). After 1 month of treat- 
ment their X-ray pictures were stable except in four cases 
with slight regression. 
There was no correlation between LPPs and ESR, WBC 
or body temperature in patients from the group II before 
treatment and after 1 month of therapy (P>O.O5). 
At the end of the treatment (after 6 months) patients 
from the group I had marked fibrotic changes on their 
X-ray (narrowed affected zones, shifted mediastinum, 
elevation of diaphragm and hilum, many linear shadows). 
Patients from the group II had only few linear shadows on 
their X-ray. 
Discussion 
In our study we have demonstrated that LPPs were elevated 
in patients with active pulmonary TB, which provides the 
evidence for enhanced free-radical-mediated processes. 
Moreover, the high concentrations of CD and MDA cor- 
responded with more advanced disease. Among patients 
TABLE 1. Clinical parameters in patients with TB 
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Patients 
Temperature (“C) WBC x 10’ cells 1 - ’ 
Before After Before After 
treatment 1 month treatment 1 month 
ESRmmh-’ 
Before After 
treatment 1 month 
Advanced TB 37.7 * 0.2 36.9 f O.l* 9.7 + 0.6 8.3 f 0.4* 57 * 8 49.1 f 7** 
TB with small radiographical changes 37.1 f 0.1 36.7 zk O.l* 7.4 f 0.4 6.7 zt 0.3** 29 f 4 22.0 f 3* 
I 
Mean body temperature of two measurements at 06:OO h and 16:00 h each day. 
WBC: white blood cell count; ESR: erythrocyte sedimentation rate. 
*P<O.l% vs. value before treatment; **P<5% vs. value before treatment. 
with marked clinical manifestations of TB, large radio- 
graphical changes and positive sputum smears, concen- 
trations of CD and MDA were significantly higher than in 
patients with small changes on X-ray and negative sputum 
smears. Jack et al. (17), studying 17 selected patients with 
TB, found out that CD concentrations were significantly 
higher only in cases with active process, while thiobarbi- 
turic acid reactive substances (TBARS) were elevated both 
‘in patients with active and inactive disease. It corresponds 
with our present results showing no difference in MDA 
concentration between group II and healthy controls. This 
may be a consequence of the fact that concentration of 
MDA measured as TBARS is a relatively non-specific 
method assessing the end products of LP as well as 
oxidation products of amino acids, nucleic acids, 
carbohydrates and prostanoid metabolism (2). 
There is much evidence that LP during oxidative stress is 
common in inflammatory processes (18-21). In our pre- 
vious study we have demonstrated that LPPs were 
enhanced in serum of patients with pneumonia and gradu- 
ally declined during recovery (3). Recently Hull et al. (21) 
found that increased serum LPPs in children with cystic 
fibrosis were associated withs the presence of pulmonary 
inflammation. This indicates that CD and other LPPs could 
be used as indicators of oxidative tissue injury independent 
of the species of pathogenic bacteria. Unlike bacterial 
pneumonia, in patients with TB elevated levels of MDA 
and CD did not change significantly during the first month 
of anti-tuberculous therapy. This is not surprising as regres- 
sion of TB is a long-lasting process, even up to 18 months 
after diagnosis (22). 
Only in the group of smear-positive patients with 
advanced TB was there a correlation between the concen- 
tration of CD and body temperature (r=0.43, PcO.05). 
These results are in agreement with Ward et ~1,‘s study (23) 
pointing out that CD is a more sensitive indicator of 
free-radical-mediated processes related to inflammation 
than MDA. Other investigators found a correlation 
between Co- and non-specific markers of inflammation 
such as ESR and the serum level of C-reactive protein 
(321). 
It has been shown that LP increased synthesis of TGF-p 
(transforming growth factor B) (24), which plays a key role 
in tissue repair and fibrogenesis (25). On one hand it 
stimulates synthesis of procollagen type I and fibronectin 
(26), while on the other it downregulates the gene expres- 
sion of collagenase (27). We suppose that high concen- 
trations of CD and MDA in serum of patients with 
advanced TB, not only at the onset of the disease but also 
during treatment, may contribute to fibrosis of the lungs. 
Indeed, all patients from group I revealed marked fibrotic 
changes on X-ray at the end of therapy, while patients from 
the group II exhibited only small changes and the concen- 
trations of CD and MDA in this group were lower than in 
patients from group I. Such a relationship has been shown 
in interstitial pulmonary fibrosis caused by bleomycin in an 
animal model (28). However, our hypothesis on the role of 
LPPs in fibrogenesis in tuberculosis should be verified in 
quantitative studies. 
During the last few years, new therapeutic possibilities 
have been explored to control intracellular infections. It 
was shown that selective iron depletion (desferrioxamine) 
could prevent the damage associated with ROS and inhib- 
ited the intracellular infection of Plasmodium falciparum 
(29). It might be of particular importance in elderly, in 
whom oxidative stress during anti-tuberculous therapy is 
higher than in younger patients and who are at a greater 
risk of lung damage because of poor antioxidant mech- 
anisms (30). Up to now there have been conflicting data 
about the role of ROS and RN1 in host defence against 
mycobacteria (31,32). In future investigations, if the benefi- 
cial effect of the scavengers of toxic oxygen or nitrogen 
species on lung injury outweighs their influence on the 
inhibition of the growth of mycobacteria, antioxidants may 
be very useful in anti-tuberculous treatment. 
In summary, we found that, as in bacterial pneu- 
monia (3), lung inflammation due to Mycobacterium 
tuberculosis is accompanied by enhanced lipid peroxidation. 
The serum levels of LPPs were higher in subjects with 
advanced TB than in those with only small radiographical 
changes. This suggests the presence of systemic oxidative 
stress in these patients in response to M tuberculosis 
infection. 
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